Gain Therapeutics (GANX) Stock Forecast, Price Target & Predictions
GANX Stock Forecast
Gain Therapeutics stock forecast is as follows: an average price target of $7.00 (represents a 348.72% upside from GANX’s last price of $1.56) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
GANX Price Target
The average price target for Gain Therapeutics (GANX) is $7.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $4.00. This represents a potential 348.72% upside from GANX's last price of $1.56.
GANX Analyst Ratings
According to 14 Wall Street analysts, Gain Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for GANX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (85.71%), 1 'Hold' (7.14%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).
Gain Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2022 | Chardan Capital | $4.00 | $3.15 | 26.98% | 156.41% | |
| Nov 13, 2022 | Thomas Shrader | BTIG | $10.00 | $3.21 | 211.53% | 541.03% |
The latest Gain Therapeutics stock forecast, released on Dec 09, 2022 by Chardan Capital company, set a price target of $4.00, which represents a 26.98% increase from the stock price at the time of the forecast ($3.15), and a 156.41% increase from GANX last price ($1.56).
Gain Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.56 | $1.56 | $1.56 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Gain Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gain Therapeutics's last price of $1.56. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Maxim Group | Buy | Buy | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 12, 2023 | Macquarie | Outperform | Initialise | |
| Sep 12, 2023 | Cowen & Co. | Outperform | Initialise | |
| Sep 12, 2023 | Canaccord Genuity | Buy | Initialise | |
| Sep 12, 2023 | Seaport Global | Sell | Initialise | |
| Sep 12, 2023 | RBC Capital | Outperform | Initialise | |
| Sep 12, 2023 | Deutsche Bank | Buy | Initialise | |
| Sep 12, 2023 | B. Riley Securities | Neutral | Buy | Initialise |
| Sep 12, 2023 | Scotiabank | Sector Perform | Initialise | |
| May 15, 2023 | Chardan Capital | Buy | Buy | Hold |
| Dec 09, 2022 | Chardan Capital | Buy | Initialise | |
| Nov 14, 2022 | EF Hutton | Buy | Buy | Hold |
| Nov 13, 2022 | BTIG | Buy | Buy | Hold |
| Aug 19, 2022 | B. Riley Securities | Neutral | Downgrade | |
| Aug 19, 2022 | B. Riley | Buy | Downgrade |
Gain Therapeutics's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company gave GANX a "Buy" rating, the same as its previous rate.
Gain Therapeutics Financial Forecast
Gain Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $55.18K | - | $95.10K | $45.01K | - | $15.97K | $5.27K |
| Avg Forecast | $33.33K | $33.33K | $33.33K | $33.33K | $23.33K | $10.00K | $400.00K | $120.00K | $250.00K | $337.50K | $1.01M | $10.00K | $51.50K | $31.67K | $39.00K | $51.60K | $20.00K | $4.96K |
| High Forecast | $33.33K | $33.33K | $33.33K | $33.33K | $23.33K | $10.00K | $400.00K | $120.00K | $250.00K | $337.50K | $1.01M | $10.00K | $51.50K | $31.67K | $39.00K | $51.60K | $20.00K | $5.96K |
| Low Forecast | $33.33K | $33.33K | $33.33K | $33.33K | $23.33K | $10.00K | $400.00K | $120.00K | $250.00K | $337.50K | $1.01M | $10.00K | $51.50K | $31.67K | $39.00K | $51.60K | $20.00K | $3.97K |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 5.52% | - | 3.00% | 1.15% | - | 0.80% | 1.06% |
Gain Therapeutics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $1.01M, with a low forecast of $1.01M, and a high forecast of $1.01M. GANX's average Quarter revenue forecast represents a 1725.16% increase compared to the company's last Quarter revenue of $55.18K (Mar 23).
Gain Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | $-4.41M | $-4.89M | $-7.73M | $-5.19M | $-4.78M | $-5.22M | $-3.30M | - | $-4.65M | $-2.44M |
| Avg Forecast | $-33.33K | $-33.33K | $-33.33K | $-33.33K | $-23.33K | $-10.00K | $-400.00K | $-120.00K | $-250.00K | $-337.50K | $-1.01M | $-10.00K | $-51.50K | $-31.67K | $-4.06M | $-51.60K | $-20.00K | $-1.02M |
| High Forecast | $-33.33K | $-33.33K | $-33.33K | $-33.33K | $-23.33K | $-10.00K | $-400.00K | $-120.00K | $-250.00K | $-337.50K | $-1.01M | $-10.00K | $-51.50K | $-31.67K | $-3.25M | $-51.60K | $-20.00K | $-819.18K |
| Low Forecast | $-33.33K | $-33.33K | $-33.33K | $-33.33K | $-23.33K | $-10.00K | $-400.00K | $-120.00K | $-250.00K | $-337.50K | $-1.01M | $-10.00K | $-51.50K | $-31.67K | $-4.87M | $-51.60K | $-20.00K | $-1.23M |
| Surprise % | - | - | - | - | - | - | - | - | 17.63% | 14.47% | 7.68% | 518.69% | 92.75% | 164.73% | 0.81% | - | 232.71% | 2.39% |
undefined analysts predict GANX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gain Therapeutics's previous annual EBITDA (undefined) of $NaN.
Gain Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 7 |
| Net Income | - | - | - | - | - | - | - | - | $-4.57M | $-4.72M | $-7.69M | $-5.14M | $-4.56M | $-5.09M | $-3.27M | - | $-4.66M | $-2.45M |
| Avg Forecast | $-4.33M | $-4.07M | $-4.42M | $-4.69M | $-4.62M | $-5.50M | $-5.17M | $-8.25M | $-8.28M | $-11.83M | $-8.17M | $-10.45M | $-8.60M | $-5.81M | $-4.07M | $-9.24M | $-6.82M | $-1.03M |
| High Forecast | $-4.33M | $-4.07M | $-4.42M | $-4.43M | $-4.13M | $-5.50M | $-5.17M | $-8.25M | $-7.76M | $-11.83M | $-8.17M | $-10.45M | $-8.60M | $-5.81M | $-3.25M | $-9.24M | $-6.82M | $-821.48K |
| Low Forecast | $-4.33M | $-4.07M | $-4.42M | $-4.69M | $-5.59M | $-5.50M | $-5.17M | $-8.25M | $-8.54M | $-11.83M | $-8.17M | $-10.45M | $-8.60M | $-5.81M | $-4.88M | $-9.24M | $-6.82M | $-1.23M |
| Surprise % | - | - | - | - | - | - | - | - | 0.55% | 0.40% | 0.94% | 0.49% | 0.53% | 0.87% | 0.80% | - | 0.68% | 2.39% |
Gain Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GANX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Gain Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 7 |
| SG&A | - | - | - | - | - | - | - | - | $2.03M | $2.52M | $3.74M | $2.49M | $2.79M | $2.69M | $1.78M | - | $2.19M | $1.05M |
| Avg Forecast | $2.41M | $2.41M | $2.41M | $2.41M | $1.69M | $723.32K | $28.93M | $8.68M | $18.08M | $24.41M | $72.85M | $723.32K | $3.72M | $2.29M | $2.81M | $3.72M | $1.44M | $358.31K |
| High Forecast | $2.41M | $2.41M | $2.41M | $2.41M | $1.69M | $723.32K | $28.93M | $8.68M | $18.08M | $24.41M | $72.85M | $723.32K | $3.72M | $2.29M | $2.81M | $3.72M | $1.44M | $429.90K |
| Low Forecast | $2.41M | $2.41M | $2.41M | $2.41M | $1.69M | $723.32K | $28.93M | $8.68M | $18.08M | $24.41M | $72.85M | $723.32K | $3.72M | $2.29M | $2.81M | $3.72M | $1.44M | $286.57K |
| Surprise % | - | - | - | - | - | - | - | - | 0.11% | 0.10% | 0.05% | 3.45% | 0.75% | 1.18% | 0.63% | - | 1.51% | 2.93% |
Gain Therapeutics's average Quarter SG&A projection for Mar 24 is $8.68M, based on 2 Wall Street analysts, with a range of $8.68M to $8.68M. The forecast indicates a 326.89% rise compared to GANX last annual SG&A of $2.03M (Dec 23).
Gain Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 7 |
| EPS | - | - | - | - | - | - | - | - | $-0.29 | $-0.37 | $-0.62 | $-0.43 | $-0.38 | $-0.43 | $-0.28 | - | $-0.39 | $-0.50 |
| Avg Forecast | $-0.16 | $-0.15 | $-0.17 | $-0.18 | $-0.17 | $-0.21 | $-0.19 | $-0.31 | $-0.31 | $-0.45 | $-0.31 | $-0.39 | $-0.45 | $-0.30 | $-0.35 | $-0.48 | $-0.36 | $-0.32 |
| High Forecast | $-0.16 | $-0.15 | $-0.17 | $-0.17 | $-0.16 | $-0.21 | $-0.19 | $-0.31 | $-0.29 | $-0.45 | $-0.31 | $-0.39 | $-0.45 | $-0.30 | $-0.35 | $-0.48 | $-0.36 | $-0.32 |
| Low Forecast | $-0.16 | $-0.15 | $-0.17 | $-0.18 | $-0.21 | $-0.21 | $-0.19 | $-0.31 | $-0.32 | $-0.45 | $-0.31 | $-0.39 | $-0.45 | $-0.30 | $-0.35 | $-0.48 | $-0.36 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | 0.83% | 2.01% | 1.09% | 0.85% | 1.42% | 0.81% | - | 1.10% | 1.58% |
According to undefined Wall Street analysts, Gain Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GANX previous annual EPS of $NaN (undefined).
Gain Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.29 | $14.00 | 4727.59% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| GANX | Gain Therapeutics | $1.68 | $7.00 | 316.67% | Buy |
| CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
| CUE | Cue Biopharma | $1.06 | $3.00 | 183.02% | Buy |
| ELVN | Enliven Therapeutics | $24.39 | $39.50 | 61.95% | Buy |
| NAMS | NewAmsterdam Pharma Company | $26.61 | $39.33 | 47.80% | Buy |